株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

女性の性機能障害:パイプライン製品の分析

Female Sexual Dysfunction - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 192588
出版日 ページ情報 英文 83 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.77円で換算しております。
Back to Top
女性の性機能障害:パイプライン製品の分析 Female Sexual Dysfunction - Pipeline Review, H2 2016
出版日: 2016年12月21日 ページ情報: 英文 83 Pages
概要

女性の性機能障害は、通常の性行為におけるさまざまな身体的段階の一部または全部を健全に経験できない場合に生じます。素因として、鬱病や不安神経症、心臓・血管病、肝臓または腎臓障害、特定の薬剤(抗鬱薬、高血圧薬など)などが挙げられます。治療は、エストロゲン療法が行われます。

当レポートでは、女性の性機能障害に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

女性の性機能障害の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • Apricus Biosciences, Inc.
  • Emotional Brain BV
  • EndoCeutics, Inc.
  • M et P Pharma AG
  • Palatin Technologies, Inc.
  • Re-Pharm Limited
  • TherapeuticsMD, Inc.
  • Valeant Pharmaceuticals International, Inc.

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8841IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Sexual Dysfunction - Pipeline Review, H2 2016, provides an overview of the Female Sexual Dysfunction (Women's Health) pipeline landscape.

Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Sexual Dysfunction - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Sexual Dysfunction (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 6, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Female Sexual Dysfunction (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Female Sexual Dysfunction (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Female Sexual Dysfunction (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Female Sexual Dysfunction (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction (Women's Health)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Female Sexual Dysfunction (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Female Sexual Dysfunction (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Female Sexual Dysfunction Overview
  • Therapeutics Development
  • Pipeline Products for Female Sexual Dysfunction - Overview
    • Pipeline Products for Female Sexual Dysfunction - Comparative Analysis
    • Female Sexual Dysfunction - Therapeutics under Development by Companies
    • Female Sexual Dysfunction - Therapeutics under Investigation by Universities/Institutes
  • Female Sexual Dysfunction - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Female Sexual Dysfunction - Products under Development by Companies
  • Female Sexual Dysfunction - Products under Investigation by Universities/Institutes
  • Female Sexual Dysfunction - Companies Involved in Therapeutics Development
    • Allergan Plc
    • Apricus Biosciences Inc
    • Emotional Brain BV
    • Fabre-Kramer Pharmaceuticals Inc
    • GlaxoSmithKline Plc
    • M et P Pharma AG
    • Palatin Technologies Inc
    • Re-Pharm Ltd
    • TherapeuticsMD Inc
    • Valeant Pharmaceuticals International Inc
  • Female Sexual Dysfunction - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (sildenafil citrate + testosterone) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AB-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alprostadil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bremelanotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • estradiol acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FKW-00GA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gepirone hydrochloride ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S1B-3006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S1B-307 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SIP-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Sexual Dysfunction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Dopamine D2 Receptor for Sexual Dysfunction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPT-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TBS-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WC-3011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Female Sexual Dysfunction - Dormant Projects
  • Female Sexual Dysfunction - Discontinued Products
  • Female Sexual Dysfunction - Product Development Milestones
    • Featured News & Press Releases
      • Nov 01, 2016: Bremelanotide Meets Co-Primary Endpoints in Palatins Phase 3 Trials for Hypoactive Sexual Desire Disorder
      • Sep 23, 2016: Palatin Technologies Presents Bremelanotide Neurobiology and Treatment Efficacy Review at World Meeting on Sexual Medicine
      • Sep 22, 2016: TherapeuticsMD Announces Multiple Presentations Related to Yuvvexy (TX-004HR) at Two Upcoming Medical Conferences
      • Sep 19, 2016: TherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act (PDUFA) Date for Yuvvexy (TX-004HR)
      • Aug 04, 2016: Palatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder
      • Jul 07, 2016: TherapeuticsMD Announces New Drug Application Submission for Yuvvexy (TX-004HR)
      • Jun 30, 2016: Catalent Announces Agreement To Commercially Supply Palatin Technologies' New Bremelanotide Female Sexual Dysfunction Product In Pen Injectors
      • Jun 29, 2016: TherapeuticsMD Announces Filing Timeline for Yuvvexy (TX-004HR) New Drug Application
      • May 14, 2016: TherapeuticsMD Presents Poster at ACOG 2016 with Additional Secondary Endpoint Data from Phase 3 Rejoice Trial
      • Mar 02, 2016: TherapeuticsMD to Present Data from Phase 3 Rejoice Trial at Upcoming Investor & Medical Conferences
      • Feb 26, 2016: Palatin Technologies Presents Bremelanotide Alcohol Interaction Study at International Society for the Study of Womens Sexual Health Annual Meeting
      • Feb 18, 2016: TherapeuticsMD Announces Poster Presentations at International Society for the Study of Women's Sexual Health Annual Meeting
      • Feb 08, 2016: Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction
      • Dec 10, 2015: Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Female Sexual Dysfunction, H2 2016
  • Number of Products under Development for Female Sexual Dysfunction - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Female Sexual Dysfunction - Pipeline by Allergan Plc, H2 2016
  • Female Sexual Dysfunction - Pipeline by Apricus Biosciences Inc, H2 2016
  • Female Sexual Dysfunction - Pipeline by Emotional Brain BV, H2 2016
  • Female Sexual Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2016
  • Female Sexual Dysfunction - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Female Sexual Dysfunction - Pipeline by M et P Pharma AG, H2 2016
  • Female Sexual Dysfunction - Pipeline by Palatin Technologies Inc, H2 2016
  • Female Sexual Dysfunction - Pipeline by Re-Pharm Ltd, H2 2016
  • Female Sexual Dysfunction - Pipeline by TherapeuticsMD Inc, H2 2016
  • Female Sexual Dysfunction - Pipeline by Valeant Pharmaceuticals International Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Female Sexual Dysfunction - Dormant Projects, H2 2016
  • Female Sexual Dysfunction - Dormant Projects (Contd..1), H2 2016
  • Female Sexual Dysfunction - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Female Sexual Dysfunction, H2 2016
  • Number of Products under Development for Female Sexual Dysfunction - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top